Antithymocyte globulin - Sanofi Genzyme

Drug Profile

Antithymocyte globulin - Sanofi Genzyme

Alternative Names: anti-thymocyte globulin; anti-thymocyte globulin (rabbit); Antithymocyte immunoglobulin; ATG; Polyclonal rabbit antithymocyte globulin; Rabbit antithymocyte globulin; Rabbit-ATG; rATG; Thymoglobulin; Thymoglobuline

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer Cedars-Sinai Medical Center; Genzyme Corporation; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi Genzyme; Sanofi Pasteur; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Bone marrow transplant rejection; Graft-versus-host disease; Liver transplant rejection; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II Heart transplant rejection; Myelodysplastic syndromes; Type 1 diabetes mellitus

Most Recent Events

  • 23 Oct 2018 No development reported - Phase-II for Liver transplant rejection (Combination therapy, Prevention) in USA (IV)
  • 13 Sep 2018 Phase-II clinical trials in Heart transplant rejection (Prevention) in USA (IV) (NCT03292861)
  • 24 Jan 2018 Sanofi (Beijing) Pharmaceutical initiates a clinical trial for Transplant rejection in China (ChiCTR-ROC-17011235)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top